Matos Dunbar works with your primary care doctor or endocrinologist to adjust your other medications
Healthcare professionals should be aware that: Patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should be carefully evaluated before prescribing Routine calcitonin measurement is not recommended for patients without risk factors, as per UK guidance [23] [24] Patients should be counselled about symptoms of thyroid tumours, including a neck mass, dysphagia, dyspnoea, or persistent hoarseness The theoretical risk must be balanced against the proven cardiovascular and metabolic benefits of these medicines in appropriate patient populations
2730 Studies have shown that GLP-1RAs can inhibit carotid body chemoreceptor activity, reducing sympathetic nervous system outflow
GLP-1 receptor agonists, such as Wegovy, which contain the active ingredient semaglutide, are a class of medications widely used for obesity and type 2 diabetes
But as someone who prescribes only legitimate GLP-1 therapies to people with obesity and weight-related metabolic diseases, I need to say this: Microdosing GLP-1s is not a thing
